Physician profile
Micky Chun
NPI 1306821434
$6,910.55
in general payments reported to CMS, 2019-2025
32 companies · $1,956 in 2025
The $1,956 reported for 2025 was more than what 89% of Nephrology (Internal Medicine) providers received nationally (typical 2025 total: $311).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $868 · 2020: $431 · 2021: $561 · 2022: $588 · 2023: $1,189 · 2024: $1,318 · 2025: $1,956.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $4,374 · Education: $89.19.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $4,373.85 |
| Education | $89.19 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Astrazeneca Pharmaceuticals Lp | $987.81 | 2019-2025 | Farxiga, Lokelma |
| Bayer Healthcare Pharmaceuticals INC. | $887.12 | 2021-2025 | |
| Otsuka America Pharmaceutical, INC. | $826.13 | 2019-2025 | Jynarque, Voyxact |
| Vifor Pharma, INC. | $792.54 | 2019-2025 | Veltassa, Korsuva |
| Amgen INC. | $451.23 | 2019-2025 | Krystexxa, Tavneos, Parsabiv |
| Mallinckrodt Hospital Products INC. | $360.51 | 2020-2025 | Acthar |
| Travere Therapeutics, INC. | $299.98 | 2022-2025 | |
| Aurinia Pharma U.S., INC. | $287.66 | 2021-2025 | Lupkynis |
| Horizon Therapeutics Plc | $272.85 | 2019-2023 | Krystexxa |
| Novo Nordisk INC | $252.72 | 2024-2025 | Ozempic, Rybelsus, Wegovy |
| Novartis Pharmaceuticals Corporation | $235.97 | 2023-2025 | |
| Glaxosmithkline, LLC. | $143.71 | 2023 | Benlysta |
| Calliditas Therapeutics US INC. | $137.35 | 2022-2025 | Tarpeyo |
| Lilly USA, LLC | $122.56 | 2024-2025 | Jardiance |
| Ardelyx, INC. | $106.55 | 2024-2025 | Ibsrela |
Show all 32 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Opko Pharmaceuticals, LLC | $94.71 | 2025 | Rayaldee |
| Ani Pharmaceuticals, INC. | $88.30 | 2022-2023 | Purified Cortrophin Gel |
| Fresenius USA Marketing, INC. | $83.73 | 2019-2022 | |
| Mallinckrodt Enterprises LLC | $78.50 | 2019 | |
| Boehringer Ingelheim Pharmaceuticals, INC. | $73.64 | 2024-2025 | Jardiance |
| Takeda Pharmaceuticals U.S.A., INC. | $60.04 | 2019-2023 | Gattex |
| Akebia Therapeutics INC | $35.93 | 2019 | |
| Renalytix Ai, INC. | $33.77 | 2025 | Kidneyintelx Blood Collection Convenience Kit |
| Bard Peripheral Vascular, INC. | $33.06 | 2020 | |
| Scpharmaceuticals INC. | $29.39 | 2025 | |
| Alnylam Pharmaceuticals INC. | $25.84 | 2021 | |
| Sanofi Pasteur INC. | $22.94 | 2019 | |
| Pfizer INC. | $22.59 | 2024 | |
| Alexion Pharmaceuticals, INC. | $19.11 | 2022 | |
| Shire North American Group INC | $16.29 | 2019 | |
| Cumberland Pharmaceuticals, INC. | $14.79 | 2021 | |
| Daiichi Sankyo INC. | $13.23 | 2020 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Micky Chun listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.